Enovix (NASDAQ:ENVX) Hits New 12-Month Low After Analyst Downgrade

Enovix Corporation (NASDAQ:ENVX)’s stock price hit a new 52-week low during trading on Tuesday after William Blair downgraded the stock from an outperform rating to a market perform rating. The company traded as low as $3.52 and last traded at $3.60, with a volume of 33997148 shares changing hands. The stock had previously closed at $4.39.

Several other equities analysts also recently commented on the stock. JPMorgan Chase & Co. downgraded shares of Enovix from a “neutral” rating to an “underweight” rating in a report on Wednesday, May 6th. B. Riley Financial decreased their price objective on shares of Enovix from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Thursday, August 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Enovix in a research report on Wednesday, July 8th. Wall Street Zen raised Enovix from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Canaccord Genuity Group reduced their price target on Enovix from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $11.77.

Trending Headlines about Enovix

Here are the key news stories impacting Enovix this week:

• Positive Sentiment: Buy upgrade and improving estimates: Zacks upgraded Enovix to Rank #2 (Buy), citing growing optimism about the company’s earnings outlook. Separately, Zacks said ENVX is technically oversold after a steep four-week decline, while analysts have been revising earnings estimates higher—factors that could support a near-term rebound. Enovix upgraded to Buy Why Enovix’s trend might reverse
• Positive Sentiment: CEO transition described as strategic continuity: Enovix said the leadership change is a “CEO transition, not a strategy transition,” reaffirmed its third-quarter 2026 guidance, and reported approximately $552 million in cash. The sizable cash balance may ease near-term financing concerns and support continued development. Enovix CEO transition webcast
• Neutral Sentiment: Unusually high trading activity in Enovix call options indicates elevated speculative interest, but the report does not establish whether investors are positioning for a sustained rally or further volatility. Enovix call option activity
• Negative Sentiment: Analyst downgrade and recent low: William Blair cut ENVX to Market Perform, and the stock recently reached a new 12-month low after the downgrade. Reports also attributed the broader decline in battery-development stocks to sharply higher Treasury yields, which pressure speculative companies. William Blair downgrades Enovix Higher yields pressure speculative growth stocks

Institutional Investors Weigh In On Enovix

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ENVX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Enovix by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 98,318 shares of the company’s stock worth $722,000 after acquiring an additional 4,780 shares in the last quarter. NewEdge Advisors LLC raised its stake in shares of Enovix by 10.4% during the first quarter. NewEdge Advisors LLC now owns 26,257 shares of the company’s stock valued at $193,000 after acquiring an additional 2,481 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Enovix by 65.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,137,777 shares of the company’s stock valued at $8,351,000 after purchasing an additional 449,934 shares during the period. Caxton Associates LLP purchased a new stake in shares of Enovix in the first quarter valued at approximately $190,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Enovix by 18.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 358,023 shares of the company’s stock valued at $2,628,000 after purchasing an additional 55,676 shares during the period. Institutional investors own 50.92% of the company’s stock.

Enovix Stock Performance

The company has a market cap of $746.13 million, a P/E ratio of -4.20 and a beta of 2.32. The firm has a 50 day moving average of $5.13 and a 200-day moving average of $5.78. The company has a quick ratio of 9.37, a current ratio of 9.71 and a debt-to-equity ratio of 2.46.

Enovix (NASDAQ:ENVX) last issued its earnings results on Wednesday, August 12th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. Enovix had a negative return on equity of 64.50% and a negative net margin of 473.89%.The business had revenue of $9.02 million during the quarter, compared to analyst estimates of $8.43 million. During the same period in the previous year, the company posted ($0.13) EPS. Enovix’s revenue was up 20.8% on a year-over-year basis. Enovix has set its Q3 2026 guidance at -0.170–0.130 EPS. As a group, sell-side analysts anticipate that Enovix Corporation will post -0.78 EPS for the current fiscal year.

About Enovix

Enovix Corporation (NASDAQ: ENVX) develops and manufactures advanced lithium-ion battery cells with a patented three-dimensional silicon-anode architecture. The company’s core focus is on delivering high energy density, improved safety, and longer cycle life compared to conventional graphite-based cells. Enovix’s technology targets a range of applications, including consumer electronics, wearable devices, electric vehicles and stationary energy storage systems.

Founded in 2011 and headquartered in Fremont, California, Enovix has built pilot production capability and is scaling up manufacturing capacity to meet growing demand.